Immunic, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 93.61 million compared to USD 120.41 million a year ago. Basic loss per share from continuing operations was USD 2.11 compared to USD 3.78 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 USD | +1.63% | +1.63% | -16.67% |
May. 08 | Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.67% | 113M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.31% | 22.67B | |
-9.93% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- IMUX Stock
- News Immunic, Inc.
- Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023